Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial.

Autor: Horndalsveen H; Department of Oncology, Oslo University Hospital, Norway.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Norway., Alver TN; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Norway.; Department of Clinical Medicine, University of Oslo, Norway., Dalsgaard AM; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Norway., Rogg LV; Department of Oncology, Oslo University Hospital, Norway., Helbekkmo N; Department of Pulmonology, University Hospital of North Norway, Tromsø, Norway., Grønberg BH; Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Norway., Halvorsen TO; Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Norway., Ramberg C; Department of Medical Physics, Oslo University Hospital, Norway., Haakensen VD; Department of Oncology, Oslo University Hospital, Norway.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Norway., Öjlert ÅK; Department of Oncology, Oslo University Hospital, Norway.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Norway., Bjaanaes MM; Department of Oncology, Oslo University Hospital, Norway., Helland Å; Department of Oncology, Oslo University Hospital, Norway.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Norway.; Department of Clinical Medicine, University of Oslo, Norway.
Jazyk: angličtina
Zdroj: Molecular oncology [Mol Oncol] 2023 Mar; Vol. 17 (3), pp. 487-498. Date of Electronic Publication: 2022 Nov 22.
DOI: 10.1002/1878-0261.13330
Abstrakt: The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non-small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this phase II trial, we investigated the toxicity, systemic responses and circulating tumour DNA responses in patients (n = 21) with advanced non-small-cell lung cancer treated with atezolizumab and stereotactic body radiotherapy in the second or later line. We found the combined treatment to be safe with grade 3 toxicity reported in three patients. As the best overall response, four patients had a partial response, eight had stable disease and five had progressive disease. Median overall survival time was still not reached after a median follow-up of 26.5 months and 10/15 patients with programmed death-ligand 1 negative tumours were alive >18 months after the start of the study treatment. ctDNA was detectable at baseline in 11 patients. A rapid decline in ctDNA to <30% of baseline levels was seen in three patients, two of which were radiographic responders and one was considered clinically benefiting from therapy for almost 1 year.
(© 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
Databáze: MEDLINE
Externí odkaz: